Journal
HEART FAILURE CLINICS
Volume 7, Issue 2, Pages 195-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2010.12.003
Keywords
Implantable cardioverter-defibrillator; Ventricular arrhythmia; Antiarrhythmic drug therapy; Adjuvant therapy; ICD shocks
Categories
Ask authors/readers for more resources
The implantable cardioverter-defibrillator (ICD) is the standard of care in patients with ischemic and nonischemic cardiomyopathy who are at high risk for arrhythmic events and sudden cardiac death. Although an ICD saves life, ICD shocks are emotionally and physically debilitating. Most patients receive adjuvant antiarrhythmic drug therapy to circumvent episodes of recurrent ventricular and supraventricular arrhythmias. Antiarrhythmic drugs including beta-blockers, sotalol, amiodarone, and azimilide are effective at reducing the shock burden. This article describes data supporting the need for and potential risks and benefits of adjuvant antiarrhythmic drug therapy and examines the benefits and pitfalls of the same in ICD-implanted patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available